Your selection basket is empty.
Define a selection of ETFs which you would like to compare.
Add an ETF by clicking "Compare" on an ETF profile or by checkmarking an ETF in the ETF search.
TER
0.40% p.a.
Distribution policy
Accumulating
Replication
Synthetic
Fund size
GBP 330 m
Inception Date
6 November 2014
Advertisement
Capital at risk
Overview
Advertisement
Start now: Build your own ETF with Pies, choosing from 13,000 stocks & ETFs. Open account Capital at risk. Execution-only services.
Description
The Invesco Nasdaq Biotech UCITS ETF seeks to track the Nasdaq Biotechnology index. The Nasdaq Biotechnology index tracks Nasdaq listed companies primarily engaged in biomedical research to develop new treatments and cures for human disease.
Documents
Chart
Basics
Data
| Index | Nasdaq Biotechnology |
| Investment focus | Equity, United States, Health Care |
| Fund size | GBP 330 m |
| Total expense ratio | 0.40% p.a. |
| Replication | Synthetic (Unfunded swap) |
| Legal structure | ETF |
| Strategy risk | Long-only |
| Sustainability | No |
| Fund currency | USD |
| Currency risk | Currency unhedged |
| Volatility 1 year (in GBP) | 22.91% |
| Inception/ Listing Date | 6 November 2014 |
| Distribution policy | Accumulating |
| Distribution frequency | - |
| Fund domicile | Ireland |
| Fund Provider | Invesco |
| Fund Structure | Open-ended Investment Company (OEIC) |
| UCITS compliance | Yes |
| Administrator | Northern Trust International Fund Administration Services (Ireland) Limited |
| Investment Advisor | Invesco Capital Management LLC |
| Custodian Bank | Northern Trust Fiduciary Services (Ireland) Limited |
| Revision Company | PricewaterhouseCoopers |
| Fiscal Year End | 30 November |
| Swiss representative | BNP Paribas, Paris, succursale de Zurich |
| Swiss paying agent | BNP Paribas, Paris, succursale de Zurich |
| Germany | 30% tax rebate |
| Switzerland | ESTV Reporting |
| Austria | Tax Reporting Fund |
| UK | UK Reporting |
| Indextype | Total return index |
| Swap counterparty | Goldman Sachs|J.P. Morgan|Morgan Stanley |
| Collateral manager | |
| Securities lending | No |
| Securities lending counterparty |
Similar ETFs
This section provides you with information on other ETFs with a similar investment focus to the Invesco Nasdaq Biotech UCITS ETF.
Similar ETFs via ETF search
Similar ETFs via investment guides
How do you like our ETF profile? Here you'll find our Questionnaire.
Performance
Returns overview
| YTD | +25.49% |
| 1 month | +5.49% |
| 3 months | +19.68% |
| 6 months | +39.71% |
| 1 year | +20.01% |
| 3 years | +23.96% |
| 5 years | +27.20% |
| Since inception (MAX) | +129.49% |
| 2024 | +0.51% |
| 2023 | -1.50% |
| 2022 | +0.33% |
| 2021 | +0.93% |
Monthly returns in a heat map
Risk
Risk metrics in this section:
- Volatility, annualised, measured for 1, 3 and 5 year periods. The annualised volatility reflects the degree of price fluctuations during a one year period. The higher the volatility, the more significantly the price of the asset (stock, ETF, etc.) has changed in the past. Assets with higher volatility are generally considered more risky. We calculate the volatility based on the data for the past 1, 3 and 5 years so that you can see if price fluctuations for the ETF became stronger or weaker over time.
- Return per risk for 1, 3 and 5 year periods. This is the annualised (i.e. converted to a one year period) past return divided by the past annualised volatility. The metric puts the historical return of an asset in relation to its historical risk and gives you a retrospective indication of the degree of price fluctuation you had to bear with in order to obtain the return. We calculate this parameter for 1, 3 and 5 year periods to display its evolution over time.
- Maximum drawdown for a period. This shows the worst possible loss an investor could have suffered during the respective period, by first buying and subsequently selling the asset at the least favourable prices. For example, if there was the following sequence of daily ETF prices: 10€, 5€, 12€, 20€, an investor would have suffered the worst loss by buying for 10€ and subsequently selling for 5€. Therefore in this case the maximum drawdown would be (5€ - 10€)/10€ = -50%.
Risk overview
| Volatility 1 year | 22.91% |
| Volatility 3 years | 20.10% |
| Volatility 5 years | 22.85% |
| Return per risk 1 year | 0.87 |
| Return per risk 3 years | 0.37 |
| Return per risk 5 years | 0.22 |
| Maximum drawdown 1 year | -21.18% |
| Maximum drawdown 3 years | -23.04% |
| Maximum drawdown 5 years | -30.71% |
| Maximum drawdown since inception | -33.80% |
Rolling 1 year volatility
Stock exchange
Listings
| Listing | Trade Currency | Ticker | Bloomberg / iNAV Bloomberg Code | Reuters RIC / iNAV Reuters | Market Maker |
|---|---|---|---|---|---|
| gettex | EUR | NBTK | - - | - - | - |
| Borsa Italiana | USD | - | SBIO IM SBIOINE | SBIO.MI 0J1KINAV.DE | Commerzbank KCG |
| Borsa Italiana | EUR | SBIO | SBIO IM SBIOINE | SBIO.MI SBIOUSiv.P | Commerzbank KCG |
| Euronext Amsterdam | EUR | SBIO | SBIO NA SBIOINE | SBIO.AS SBIOUSiv.P | Commerzbank KCG |
| London Stock Exchange | GBX | SBIX | SBIX LN SBIOGBIV | SBIX.L SBIOGBiv.P | Commerzbank KCG |
| London Stock Exchange | USD | SBIO | SBIO LN SBIOIN | SBIO.L SBIOUSiv.P | Commerzbank KCG |
| SIX Swiss Exchange | USD | SBIO | SBIO SW SBIOIN | SBIO.S SBIOUSiv.P | Commerzbank KCG |
| XETRA | EUR | NBTK | NBTK GR SBIOINE | NBTKG.DE SBIOUSiv.P | Commerzbank KCG |
Further information
Further ETFs on the Nasdaq Biotechnology index
| Fund name | Fund Size in m € (AuM) | TER p.a. | Distribution | Replication |
|---|---|---|---|---|
| iShares Nasdaq US Biotechnology UCITS ETF | 715 | 0.35% p.a. | Accumulating | Sampling |
| iShares Nasdaq US Biotechnology UCITS ETF USD (Dist) | 44 | 0.35% p.a. | Distributing | Sampling |
Latest articles
Frequently asked questions
What is the name of SBIX?
The name of SBIX is Invesco Nasdaq Biotech UCITS ETF.
What is the ticker of Invesco Nasdaq Biotech UCITS ETF?
The primary ticker of Invesco Nasdaq Biotech UCITS ETF is SBIX.
What is the ISIN of Invesco Nasdaq Biotech UCITS ETF?
The ISIN of Invesco Nasdaq Biotech UCITS ETF is IE00BQ70R696.
What are the costs of Invesco Nasdaq Biotech UCITS ETF?
The total expense ratio (TER) of Invesco Nasdaq Biotech UCITS ETF amounts to 0.40% p.a.. These costs are withdrawn continuously from the fund assets and already included in the performance of the ETF. You don't have to pay them separately. Please have a look at our article for more information about the cost of ETFs.
Is Invesco Nasdaq Biotech UCITS ETF paying dividends?
Invesco Nasdaq Biotech UCITS ETF is an accumulating ETF. This means that dividends are not distributed to investors. Instead, dividends are reinvested in the fund on the ex-date, which leads to an increase of the ETF's share price.
What's the fund size of Invesco Nasdaq Biotech UCITS ETF?
The fund size of Invesco Nasdaq Biotech UCITS ETF is 330m GBP. See the following article for more information about the size of ETFs.
— Data provided by Trackinsight, etfinfo, Xignite Inc., gettex, FactSet and justETF GmbH. Quotes are either real-time (gettex) or 15 minutes delayed stock exchange quotes or NAVs (daily published by the fund provider). By default, ETF returns include dividend payments (if applicable). There is no warranty for completeness, accuracy and correctness for the displayed information.